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Abstract Stathmin is a cytosolic phosphoprotein that has an 
important but, as yet, undefined role in cell proliferation and 
differentiation. Induction of growth arrest and differentiation of 
HL60 cells to monocytes by phorbol 12-myristate 13-acetate is 
associated with rapid phosphorylation of the protein. Stathmin 
phosphorylation was not seen when HL60 cells were induced to 
differentiate to monocytes, by lot,25-dihydroxyvitamin D3, and 
to neutrophils, by all-trans retinoic acid and granulocyte colony 
stimulating factor. In all the above instances, stathmin expression 
was down-regulated. Thus, increased stathmin phosphorylation is 
not required for cell growth arrest or differentiation or down- 
regulation of stathmin expression. 
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I. Introduction 
Stathmin is a phylogenetically conserved, abundant cytosolic 
protein which is present within cells in non-phosphorylated and 
variously phosphorylated forms [1]. This protein has also been 
termed p19 or metablastin [2], prosolin [3], 19K [4], Lapl8 [5] 
and Op18 [6]. Both the extent to which the protein is 
phosphorylated and the level of expression of stathmin have 
been associated with cell proliferation [3,7-10], development 
[11-14] and differentiation [2,15,16]. In vitro analysis has shown 
that stathmin is phosphorylated on serine residues by MAP 
kinase [17], cAMP-dependent protein kinase [12,18] and p34 ca': 
kinase [18]. It has also been shown that the extent o which 
stathmin is phosphorylated is related to the progression of cells 
through the cell cycle, with the protein becoming maximally 
phosphorylated during G2/M [19]. 
Phosphorylation of stathmin has been described in associa- 
tion with a wide variety of cellular events [2,4,20-26]. In partic- 
ular, induction of growth arrest upon treatment of cells with 
phorbol 12-myristate 13-acetate (PMA) is accompanied by 
rapid and extensive phosphorylation f stathmin in HL60 cells 
and other myeloid cell lines [3,27,28], A431 epidermal carci- 
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noma cells [29] and proliferating peripheral blood lymphocytes 
[7]. In cell lines that subsequently undergo differentiation fol- 
lowing PMA treatment, for example HL60 and K562 cells, 
there is also a decline in the level of stathmin expression 
[27,28,30]. Findings uch as these have been used to suggest that 
stathmin phosphorylation a d subsequent down-regulation are 
important in the processes of cell growth arrest and/or differen- 
tiation. 
HL60 cells can be induced to differentiate o monocytes by 
lc~,25-dihydroxyvitamin D3 (vitD3) [30] and to neutrophils by 
all-trans retinoic acid (ATRA) together with recombinant 
human granulocyte colony stimulating factor (hrG-CSF) [31]. 
In the present report we describe the changes in the extent of 
stathmin phosphorylation a d expression following induction 
of growth arrest and differentiation of HL60 cells by these 
physiological agents. The rapid and transient hyper- 
phosphorylation f stathmin that occurs when PMA is used to 
elicit growth arrest and differentiation of HL60 cells was not 
observed when HL60 cells were induced to differentiate by 
physiological gents. As cell growth arrest occurred the propor- 
tion of stathmin that was phosphorylated decreased and the 
level of stathmin declined. 
2. Materials and methods 
2.1. Induction and quantitation fHL60 cell differentiation 
The maintenance ofthe promyeloid cell line HL60 [32] and induction 
of HL60 monocyte differentiation by treatment with PMA have been 
described previously [3]. Treatment of HL60 cells with 10 nM ATRA 
(Sigma, Poole, UK), in combination with 30 ng/ml hrG-CSF (Neupho- 
gen; Amgen, Cambridge, UK), to induce neutrophil differentiation, and 
100 nM vitD3 to induce monocyte differentiation have also been de- 
scribed previously [30,31]. HL60 cell differentiation was assessed by 
measuring the proportion of cells able to phagocytose complement 
coated yeast cells [33] and the proportion expressing the monocyte 
specific enzyme ~-napthyl acetate sterase [34]. The proportions of 
HL60 cells within compartments of the cell cycle were determined by 
flow cytometric analyses of cells that had been stained with propidium 
iodide. 
2.2. Immunohistochemistry 
The proportions of cells expressing a proliferation-associated pro- 
tein, the Ki-67 antigen [35], and stathmin following vitD3 or ATRA/ 
hrG-CSF treatment were determined by double immunostaining of 
cytocentrifuged cell preparations, as described previously [36]. The 
results are a mean ( + S.E.M.) of data from three experiments. 
2.3. Gel electrophoresis and Western blotting 
Levels of stathmin expression and the extent of phosphorylation in 
control and treated cells were determined by 1- and 2-dimensional gel 
electrophoresis followed by immunostaining ofWestern blots with an 
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antiserum tostathmin and [~251]protein A, as described previously [28]. 
Autoradiography films (Hyperfilm-MP X-ray film; Amersham Int. plc, 
Amersham) were preflashed, toallow quantitative d nsitometric analy- 
sis of the autoradiographs, and exposed at -70°C with intensifying 
screens. Autoradiographs were scanned using a laser densitometer (U1- 
troscan XL, Pharmacia LKB, Milton Keynes, UK) and analysis of gel 
scans was undertaken using Gelscan XL laser densitometer programme 
software (Pharmacia LKB). 
3. Results 
3.1. Changes in stathmin expression during HL60 monocyte 
differentiation 
Treatment of HL60 cells with 100 nM vitD3 induced mon- 
ocyte differentiation asshown by an increase in the number of 
phagocytic ells from <0.5% in untreated cells to 77 + 1% at 
day 5. The number of cells expressing the monocyte-specific 
enzyme cz-naphthyl acetate sterase increased from 1 + 0.5% to 
81 + 6%. Cell cycle analyses of vitD3 treated HL60 cells re- 
vealed a time-dependent accumulation of cells into the GdGI 
phase of the cell cycle (Fig. 1, left panel). In control cells and 
for 2 days after addition of vitD3, 52 + 8% of HL60 cells were 
in Go/G~, 43 + 8% in S and 6 + 1% in G2/M. After 5 days of 
exposure to vitD3, 90 + 2% of ilL60 cells were in G0/G1 indicat- 
ing that the majority of the cells in the culture had arrested their 
growth. 
PMA-induced monocyte differentiation f HL60 cells results 
in loss of stathmin and Ki-67 proteins, as detected by im- 
munocytochemistry [28]. Treatment of HL60 cells with vitD3 
also resulted in a decrease in the proportion of cells that stained 
positively for stathmin and the Ki-67 antigen (Fig. 1, left panel). 
On the double immunostains performed, there was a close 
relationship between strong cytoplasmic mmunopositivity for
stathmin and nuclear immunopositivity for the Ki-67 antigen. 
After 3 days of treatment with vitD3, some cells were weakly 
positive for stathmin but negative for the Ki-67 antigen, with 
the numbers of these cells decreasing with time, as described for 
PMA-treated HL60 cells [28]. 93-96% of HL60 cells in control 
cultures tained strongly for stathmin and the Ki-67 antigen. In 
vitD3-treated cultures, the proportion of cells expressing both 
proteins remained high (86%-92%) for 2 days after addition of 
vitD3. Thereafter, the proportion of cells expressing stathmin 
and Ki-67 antigen declined in a time dependent manner up to 
day 5, when 22 -+ 6% of cells were stained. 
Down-regulation of stathmin protein was quantitated by 
densitometric analyses of immunostained Western blots of cell 
extracts (Fig. 1, left panel). In exponentially growing HL60 
cultures there was a variation in the level of expression of 
stathmin of 6% (n = 3). Stathmin expression remained constant 
for up to 2 days after exposure to vitD3, thereafter there was 
a time-dependent reduction in the total level of stathmin. After 
3 days treatment with 100 nM vitD3, HL60 cells expressed 
63 _+ 16% of the level of stathmin in untreated cells and after 
5 days exposure to vitD3 only 5 + 2% of the initial level of 
stathmin was detectable. 
3.2. Changes' in stathmin expression during HL60 neutrophil 
differentiation 
HL60 cells exposed to 10 nM ATRA in combination with 30 
ng/ml hrG-CSF grew exponentially for 2 days after which time 
cell growth arrest was observed. The proportion of phagocytic 
cells increased from <0.5% to 67 + 3% at day 5. Cell cycle 
analyses of HL60 cells exposed to ATRA/hrG-CSF revealed an 
accumulation of cells in G0/G1 phase of the cell cycle (Fig. 1, 
right panel). In control cells and up to 2 days after addition of 
ATRA/hrG-CSF, 48 + 2% of HL60 cells were in G0/G~, 
44 + 2% in S and 4 + 0.5% in G2/M. After 5 days of exposure 
to ATRA/hrG-CSF, 85 + 3% of HL60 cells were in G0/Gj. The 
patterns of down-regulation f expression of stathmin and of 
Ki-67 antigen in HL60 cells that had been treated with ATRA/ 
hrG-CSF were similar to those observed in vitD3 treated HL60 
cells (Fig. 1, right panel). A high proportion of cells expressing 
both proteins (90%-92%) was observed for 2 days after addi- 
tion of ATRA/hrG-CSF. Thereafter, the proportion of cells 
expressing stathmin and Ki-67 antigen declined until after 5 
days exposure to ATRA/hrG-CSF 20 + 8% of cells were posi- 
tive. 
Quantitation of these changes in the levels of expression of 
stathmin was undertaken by Western blotting. As shown in Fig. 
1 (right panel), ATRA/hrG-CSF treatment resulted in down- 
regulation of stathmin levels in HL60 cells. After 5 days expo- 
sure to ATRA/hrG-CSF, 24 _+ 5% of the initial level of stath- 
rain was detectable. 
3.3. Stathmin phosphorylation during HL60 monocyte and 
neutrophil differentiation 
Stathmin is present within HL60 cells as a non- 
phosphorylated (n)and two phosphorylated forms (pl and p2). 
In exponentially growing HL60 cultures alow level ofphospho- 
rylation of stathmin was always detected (see Fig. 2). Stathmin 
was present as 82 + 7.% n and 18 + 7% pl (n = 21). The p2 
form was not detected. As reported previously, time course 
analyses of PMA-treated HL60 cells revealed a rapid increase 
in the phosphorylation status of stathmin [3,27] (see Fig. 3). 
After 1 h of exposure to 10 nM PMA, stathmin was present as 
20 + 7% n, 70 + 10% pl and 10 + 4% p2 (n = 5) (see Fig. 2). 
This maximal level of phosphorylation f stathmin was main- 
tained for up to 6 h after exposure to PMA. At 4 h, stathmin 
was present as 31 + 3% n, 68 _+ 4% pl and 2 + 1% p2 (n = 5). 
Thereafter, a decline in the phosphorylation status of stathmin 
was observed. After 24 h of exposure to 10 nM PMA, the level 
of phosphorylation was similar to that observed in exponen- 
tially growing cells (88 + 7% n and 12 _+ 7% pl). Treatment of 
HL60 cells for 36, 48 and 72 h with PMA resulted in a time- 
dependent dephosphorylation of stathmin. At 72 h, stathmin 
was present as 98 + 2% n and 2 + 2% pl (n = 5), which is a level 
of phosphorylation lower than that detected in exponentially 
growing HL60 cells. 
In contrast o the dramatic hanges observed after PMA- 
treatment ofHL60 cells, induction of HL60 differentiation with 
Fig. 1. Changes in stathmin expression during HL60 neutrophil and monocyte differentiation. HL60 cells were induced to differentiate to monocytes, 
by vitD3 (left panels), and to neutrophils, by ATRA/hrG-CSF (right panels). Relative levels of stathmin were measured by immunostaining of Western 
blots of cell extracts (top panels). The middle panels how the proportions of cells stained for stathmin and the Ki-67 antigen. Proportions of cells 
in the G~ (m), S (m) and G]M (A) phases of the cell cycle are shown (bottom panels). 
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Fig. 2. Treatment of HL60 cells with PMA, but not vitD3 and ATRA/ 
hrG-CSF, results in rapid stathmin phosphorylation. Autoradiographs 
of immunostained Western blots of HL60 cell extracts after treatment 
of cells for 4 hours with either PMA, ATRA/hrG-CSF or vitD3 are 
shown, n = non-phosphorylated form; pl = major phosphophorylated 
form; and p2 = minor phosphorylated form. 
Fig. 3. Changes in stathmin phosphorylation during HL60 neutrophil 
and monocyte differentiation. Immunostaining of Western blots of 
2-dimensional gels of cell extracts was undertaken to determine the 
proportions of stathmin present in a non-phosphorylated (m), and the 
two phosphorylated forms pl (D) and p2 (A). HL60 cells were induced 
to differentiate o monocytes, by PMA and by vitD3, and to neutro- 
phils, by ATRA/hrG-CSF. 
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and 0.6 + 1% pl (n = 5) and after 5 days of treatment with 
ATRA/hrG-CSF stathmin was present as 99 + 1% n and 
0.5 + 0.5% pl (n = 5). This dephosphorylation ccurred over 
the time period when the majority of cells were exiting from the 
cell cycle and when down regulation of stathmin protein and 
Ki-67 antigen were detected (Fig. 1). 
4. Discussion 
In most cell lineages tathmin expression in vivo is confined 
to cells that are, or have recently been, proliferating [36]. In this 
and in previous studies of cells in vitro, stathmin expression 
falls in association with induction of cell growth arrest 
[8,27,28,30,37]. 
Rapid and transient phosphorylation of stathmin has been 
described in cell types, including myeloid, lymphoid and epithe- 
lial cells, that growth arrest and differentiate following treat- 
ment with PMA [3,7,27--29]. Hence, it has been suggested that 
hyperphosphorylation of the protein is an important event in 
these cellular processes. However, we have described a high 
level of stathmin phosphorylation following PMA treatment of 
plasmacytoma cell lines and these cells did not undergo any 
subsequent change in their proliferative activity [28]. In addi- 
tion, PMA-induced hyperphosphorylation f stathmin has 
been related to a number of other cellular events, such as 
peptide hormone secretion [1]. It is therefore possible that this 
widely reported phosphorylation is simply a non-specific effect 
of PMA and has no direct functional significance. In this study 
it was observed that extensive phosphorylation f stathmin did 
not occur when physiological gents, as opposed to PMA, were 
used to elicit growth arrest and differentiation i HL60 cells. 
Thus, stathmin phosphorylation is not necessary for these cellu- 
lar changes to occur. This study showed that there was a grad- 
ual decrease in the proportion of phosphorylated stathmin pro- 
tein which coincided with the period during which cell growth 
arrest was occurring. This is consistent with a reduction in the 
proportion of cells in the G2/M phases of the cell cycle when 
stathmin phosphorylation is at its highest level [19]. 
It is concluded that the level of stathmin expression is linked 
to the proliferative status of cells. However, phosphorylation 
of the protein is not a consistent finding in relation to cell 
growth arrest and differentiation and so is not essential for 
these cell processes to occur. 
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